Patents Examined by Taofiq A. Solola
-
Patent number: 10894224Abstract: A system and method for removing undesirable organic compounds so that the desirable cannabinoids, terpenes, and any other beneficial organic compounds can be easily and effectively captured is provided herein. The system and method makes use of diatomaceous earth filters through which a solution containing the organic compounds is rinsed with liquid non-polar solvent. The undesirable components remain in the diatomaceous while the beneficial organic compounds pass through and are collected in a liquid solution.Type: GrantFiled: March 28, 2019Date of Patent: January 19, 2021Inventor: Caleb Mata
-
Patent number: 10894033Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: GrantFiled: February 14, 2020Date of Patent: January 19, 2021Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLCInventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
-
Patent number: 10888550Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.Type: GrantFiled: June 13, 2019Date of Patent: January 12, 2021Assignee: Janssen Pharmaceutica NVInventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Didier Jean-Claude Berthelot, Tongfei Wu
-
Patent number: 10889717Abstract: The present disclosure provides composition having at least one leuco composition conforming to Formula (I): Ar1Ar2Ar3CH??(I) wherein Ar2 and Ar3 are independently a carbocyclic aryl or heteroaryl, and Ar1 is selected from the group consisting of: unsubstituted phenyl, electron deficient carbocyclic aryl, and heteroaryl. The present disclosure also provides a method of detecting an authentic composition and test kits for detecting authentic compositions.Type: GrantFiled: October 11, 2018Date of Patent: January 12, 2021Assignee: Milliken & CompanyInventors: Sanjeev K. Dey, Haihu Qin, Gregory S. Miracle
-
Patent number: 10875834Abstract: Prodrugs and derivatives of 5-hydoxymethyl-2-furfural (5-HMF) with protected or modified aldehyde and/or alcohol moieties are provided. The prodrugs or derivatives exhibit increased bioavailability, e.g. due to having extended half-lives in circulation. The drugs are therefore administered i) at lower doses and/or ii) less frequently than 5-HMF, while still maintaining the beneficial therapeutic effects of 5-HMF.Type: GrantFiled: July 24, 2017Date of Patent: December 29, 2020Assignees: Virginia Commonwealth University, The Children's Hospital of PhiladelphiaInventors: Martin K. Safo, Guoyan Xu, Yan Zhang, Osheiza Abdulmalik
-
Patent number: 10875853Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.Type: GrantFiled: January 19, 2018Date of Patent: December 29, 2020Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Patent number: 10851050Abstract: The present disclosure discloses a biaryl urea ROR?t inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an ROR?t inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an ROR?t-related disease.Type: GrantFiled: April 16, 2020Date of Patent: December 1, 2020Assignee: FUDAN UNIVERSITYInventors: Yonghui Wang, Yafei Huang, Fazhi Yu, Ting Tang
-
Patent number: 10851095Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.Type: GrantFiled: April 30, 2019Date of Patent: December 1, 2020Assignee: ANGION BIOMEDICA CORP.Inventors: Bijoy Panicker, Lambertus J. W. M. Oehlen
-
Patent number: 10844081Abstract: Disclosed are a range of protected organoboronic acid reagents useful in the modular assembly of complex organic compounds. The reactivities of the protected organoboronic acid reagents may be varied predictably by changes to the number and identities of their substituents. Also disclosed are methods of using the protected organoboronic acid reagents in the synthesis of organic compounds.Type: GrantFiled: August 8, 2016Date of Patent: November 24, 2020Assignee: The Board of Trustees of the University of IllinoisInventors: Martin D. Burke, Michael Schmidt, Greg Morehouse, Robert W. Pipal
-
Patent number: 10836760Abstract: The invention provides compositions and methods for the treatment of presbyopia. The methods preferably comprise storing an aceclidine composition in a container having a headspace at a temperature from about 2 to about 8 degrees Celsius. The methods further comprise filling the container under an inert gas overlay and/or enclosing the container an anti-leaching material or disposing the container in a second container containing an anti-leaching material.Type: GrantFiled: October 8, 2019Date of Patent: November 17, 2020Assignee: Presbyopia Therapies LLCInventor: Gerald Horn
-
Patent number: 10836748Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.Type: GrantFiled: April 28, 2020Date of Patent: November 17, 2020Assignee: Pharvaris Netherlands B.V.Inventors: Christoph Gibson, Joern Saupe, Horst-Dieter Ambrosi, Lars Ole Haustedt
-
Patent number: 10836776Abstract: The present application relate to process for preparation of tetrahydrofuran compound of formula II, 4-Methylene tetrahydrofuran compound of formula V and tetrahydropyran compound of formula IX which are useful as intermediates for the preparation of halichondrin B analogues such as Eribulin or its pharmaceutically acceptable salts.Type: GrantFiled: November 23, 2017Date of Patent: November 17, 2020Assignee: DR. REDDY'S LABORATORIES LIMITEDInventors: Kumar Sarvesh, Debjit Basu, Raja gopal Penumandla, Prapulla Kumar Palvai
-
Patent number: 10822324Abstract: The present invention relates to a method for selectively separating propylene carbonate by adding water to reaction products comprising a polyether carbonate polyol and propylene carbonate, which are generated from a polymerization reaction of propylene oxide and carbon dioxide under a double metal cyanide (DMC) catalyst, wherein an economical and effective separation of propylene carbonate can be achieved.Type: GrantFiled: December 15, 2017Date of Patent: November 3, 2020Assignees: POSCO, RESEARCH INSTITUTE OF INDUSTRIAL SCIENCE & TECHNOLOGYInventors: Joon-Hyun Baik, Jae-Hee Ha
-
Patent number: 10815245Abstract: The present invention relates to the production of xylene derivatives from furfural and its derivatives. The invention describes new routes for converting furfural and its derivatives into xylene derivatives including novel intermediates.Type: GrantFiled: December 8, 2016Date of Patent: October 27, 2020Assignees: RHODIA OPERATIONS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Didier Morvan, Olivier Back, Raphaƫl Wischert, Eric Muller
-
Patent number: 10807981Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: June 25, 2019Date of Patent: October 20, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Patent number: 10800809Abstract: The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.Type: GrantFiled: June 6, 2019Date of Patent: October 13, 2020Assignee: Laurus Labs LimitedInventors: Sanjay Kumar Dehury, Nagaraju Mekala, Jahangeer Baba Shaik, Srinivasa Rao Buddepu, Lakshmi Kanth Kola, Venkata Sunil Kumar Indukuri, Seeta Rama Anjaneyulu Gorantla, Satyanarayana Chava
-
Patent number: 10793590Abstract: Compounds of formula (I) or formula (II), compositions and methods useful for treating and/or preventing a fungal infections are provided. wherein the substituents are as defined in the appended claims.Type: GrantFiled: June 2, 2017Date of Patent: October 6, 2020Assignees: President and Fellows of Harvard College, Wisconsin Alumni Research Foundation, Universidad de Costa RicaInventors: Ethan Van Arnam, Clarissa Sit, Antonio Ruzzini, Jon Clardy, Cameron Currie, Adrian Alberto Pinto-Tomas
-
Patent number: 10793524Abstract: Provided is a method for regenerating an aromatic amide compound into a corresponding aromatic nitrile compound, the method realizing a dehydration reaction of providing a target compound selectively at a high yield, with generation of a by-product being suppressed. Also provided is a method for producing an aromatic nitrile compound that decreases the number of steps of the dehydration reaction and significantly improves the reaction speed even at a pressure close to normal pressure. In addition, the above-described production method is applied to a carbonate ester production method to provide a method for producing a carbonate ester efficiently. The above-described methods are realized by a method for producing an aromatic nitrile compound including a dehydration reaction of dehydrating an aromatic amide compound, in which the dehydration reaction uses, as a solvent, any of 1,2-dimethoxybenzene, 1,3-dimethoxybenzene and 1,3,5-trimethoxybenzene.Type: GrantFiled: November 30, 2017Date of Patent: October 6, 2020Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Hidefumi Harada, Yousuke Shinkai, Hongyu Liu, Takehiko Isobe, Yoshinori Isahaya
-
Patent number: 10792584Abstract: A process for producing THC-O-acetate using a succession of distillation, salting-out assisted liquid-liquid extractions (SALLEs), and solvent recovery techniques. Tetrahydrocannabinol (THC) in cannabis oil reacts with acetic anhydride under reflux to produce THC-O-acetate and acetic acid. The resulting crude product is distilled and subjected to a SALLE with hexane followed by a SALLE with petroleum ether, before being distilled again in order to obtain a refined, THC-O-acetate product.Type: GrantFiled: February 6, 2020Date of Patent: October 6, 2020Assignee: Nextleaf Solutions Ltd.Inventors: Krupal Devendra Pal, Ryan Delmoral Ko, Brock Aston Hughes, Ivan Jason Casselman
-
Patent number: 10787442Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.Type: GrantFiled: December 15, 2017Date of Patent: September 29, 2020Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: John G. Catalano, Martha Alicia De La Rosa, Wieslaw Mieczyslaw Kazmierski, Vicente Samano